. 2022; 9(2): 197-200 | |||
Successful Treatment of Refractory Graft Versus Host Disease with Ruxolitinib in a Child After Autologous Stem Cell TransplantationNursah Eker, burcu tufan taş, OMER DOGRU, emel senay, Gülnur Tokuç, Ahmet KoçDepartment of Pediatric Hematology and Oncology, Marmara University Hospital, Istanbul, TurkeyIntroduction: Autologous hematopoietic stem cell transplantation(AHSCT) is an increasingly used curative treatment for some solid tumors in children. Instead of allogeneic transplantation, the risk of developing graft versus host disease (GvHD) is much lower after AHSCT. Although the clinical findings of auto-GVHD are mild and self-limited in most cases, rare cases may be severe and need intensive immunosuppressive treatment. Here, we present a case who underwent autologous HSCT due to relapsed neuroblastoma, developed steroid-refractory GvHD after AHSCT, and achieved remission using ruxolitinib. Nursah Eker, burcu tufan taş, OMER DOGRU, emel senay, Gülnur Tokuç, Ahmet Koç. Successful Treatment of Refractory Graft Versus Host Disease with Ruxolitinib in a Child After Autologous Stem Cell Transplantation. . 2022; 9(2): 197-200 Corresponding Author: burcu tufan taş, Türkiye |
|